Population pharmacokinetics of vancomycin and AUC-guided dosing in Chinese neonates and young infants

[1] Clark RH(2006)Reported medication use in the neonatal intensive care unit: data from a large national data set Pediatrics 117 1979-1987

[2] Bloom BT(2013)Use of antibacterial agents in the neonate: 50 years of experience with vancomycin administration Semin Fetal Neonatal Med 18 28-34

[3] Spitzer AR(2003)Developmental pharmacology-drug disposition, action, and therapy in infants and children N Engl J Med 349 1157-1167

[4] Gerstmann DR(2014)Vancomycin pharmacokinetic models: informing the clinical management of drug-resistant bacterial infections Expert Rev Anti-Infect Ther 12 1371-1388

[5] Jacqz-Aigrain E(2009)Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists Am J Health Syst Pharm 66 82-98

[6] Zhao W(2006)Pharmacodynamics: relation to antimicrobial resistance Am J Med 119 S37-S44

[7] Sharland M(2006)The pharmacokinetic and pharmacodynamic properties of vancomycin Clin Infect Dis 42 S35-S39

[8] van den Anker JN(2003)Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid Infect Dis Clin N Am 17 479-501

[9] Kearns GL(2011)Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children Clin Infect Dis 52 e18-e55

[10] Abdel-Rahman SM(2013)Vancomycin dosing in children and young adults: back to the drawing board Pharmacotherapy 33 1278-1287

[1] Clark RH(2006)Reported medication use in the neonatal intensive care unit: data from a large national data set Pediatrics 117 1979-1987

[2] Bloom BT(2013)Use of antibacterial agents in the neonate: 50 years of experience with vancomycin administration Semin Fetal Neonatal Med 18 28-34

[3] Spitzer AR(2003)Developmental pharmacology-drug disposition, action, and therapy in infants and children N Engl J Med 349 1157-1167

[4] Gerstmann DR(2014)Vancomycin pharmacokinetic models: informing the clinical management of drug-resistant bacterial infections Expert Rev Anti-Infect Ther 12 1371-1388

[5] Jacqz-Aigrain E(2009)Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists Am J Health Syst Pharm 66 82-98

[6] Zhao W(2006)Pharmacodynamics: relation to antimicrobial resistance Am J Med 119 S37-S44

[7] Sharland M(2006)The pharmacokinetic and pharmacodynamic properties of vancomycin Clin Infect Dis 42 S35-S39

[8] van den Anker JN(2003)Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid Infect Dis Clin N Am 17 479-501

[9] Kearns GL(2011)Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children Clin Infect Dis 52 e18-e55

[10] Abdel-Rahman SM(2013)Vancomycin dosing in children and young adults: back to the drawing board Pharmacotherapy 33 1278-1287